U.S. Markets closed

China SXT Pharmaceuticals, Inc. (SXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3617-0.0140 (-3.73%)
At close: 4:00PM EDT

0.3560 -0.01 (-1.58%)
After hours: 7:43PM EDT

China SXT Pharmaceuticals, Inc.

No.178 North Taidong Road
Taizhou 225300
86 523 8629 8290

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees97

Key Executives

NameTitlePayExercisedYear Born
Mr. Feng ZhouChairman, CEO & Interim CFO50kN/A1992
Dr. Jingzhen DengChief Scientific Officer & COO50kN/A1960
Mr. Jun ZhengExec. DirectorN/AN/A1977
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of May 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. The company was founded in 2005 and is based in Taizhou, China.

Corporate Governance

China SXT Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.